Quarterly ResultMay 5, 2026, 08:31 AM
Cogent Biosciences Q1 Net Loss Widens to $97.4M
AI Summary
Cogent Biosciences reported a significant increase in its net loss for the first quarter of 2026, reaching $97.4 million, up from $72.0 million in the prior year. This was primarily driven by a rise in operating expenses, including research and development and general and administrative costs. While the company's cash and marketable securities are expected to fund operations for at least the next 12 months, it anticipates needing additional funding for its ongoing clinical development and commercialization efforts, including the planned launch of bezuclastinib in the second half of 2026.
Key Highlights
- Net loss widened to $97.4 million in Q1 2026 from $72.0 million in Q1 2025.
- Total operating expenses increased to $103.6 million in Q1 2026 from $74.9 million in Q1 2025.
- Cash and cash equivalents decreased to $241.2 million as of March 31, 2026, from $312.0 million.
- Short-term marketable securities increased to $625.2 million as of March 31, 2026.
- Net cash used in operating activities increased to $86.9 million in Q1 2026.
- Net cash provided by financing activities was $52.5 million in Q1 2026.
- Received $45.7 million net proceeds from ATM sales in Q1 2026, with $88.6 million remaining.
- Anticipates commercial launch of bezuclastinib in the United States in H2 2026.
Price Impact
More from COGT